Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy

The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), who are frequently on long-term immunotherapies. Treatment with IVIg does not increase the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Romozzi, Marina, Bisogni, Giulia, Sabatelli, Mario, Luigetti, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798012/
https://www.ncbi.nlm.nih.gov/pubmed/33428052
http://dx.doi.org/10.1007/s10072-020-04983-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798012/
https://www.ncbi.nlm.nih.gov/pubmed/33428052
http://dx.doi.org/10.1007/s10072-020-04983-5

Ejemplares similares